Sign In
Buy OKYO
$1.55
+0.0700 (+4.73%)
At Close: Jul 24, 2026
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
07:00am, Friday, 23'rd Jan 2026
LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa
Duolingo is more game than classroom, Bank of America says in Buy upgrade
09:32am, Monday, 05'th Jan 2026
Bank of America upgraded Duolingo Inc to Buy on Monday, arguing the market is undervaluing the language-learning app by viewing it too narrowly as an...
OKYO Pharma names ophthalmology veteran Robert Dempsey as CEO
08:42am, Monday, 05'th Jan 2026
OKYO Pharma Ltd (NASDAQ:OKYO) has appointed ophthalmology veteran Robert Dempsey as its new CEO. The NASDAQ-listed, clinical-stage biopharmaceutical company said Dempsey takes on the CEO role with imm
OKYO Pharma management team to ring Nasdaq opening bell
08:49am, Friday, 19'th Dec 2025
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its executive chairman and founder, Gabriele Cerrone, along with members of the company's management team, will ring the Nasdaq Opening Bell at the Nasdaq
Nasdaq charges higher, led by Oracle and Micron
07:56am, Friday, 19'th Dec 2025
12:56pm: More data, more questions Post-shutdown economic data continued to roll in this week, including employment figures for October and November,...
OKYO Pharma to Ring the Opening Bell at Nasdaq
07:00am, Friday, 19'th Dec 2025
LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (N
OKYO Pharma Announces Chairman and Founder Acquires Shares
08:30am, Monday, 15'th Dec 2025
LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corne
Nasdaq tumbles to close out brutal week for tech stocks
11:18am, Friday, 12'th Dec 2025
4:15pm: Rising yields hit tech Stocks limped into the weekend on Friday, with tech once again dragging the major indexes lower as investors rotated out of...
FTSE 100 Live: London stocks pare gains; US futures point to mixed start
08:43am, Friday, 12'th Dec 2025
FTSE down 4 points at 9,699 UK GDP slips 0.1% in October Silver touches a new high US futures point to mixed start 1.42pm: Trump moves to loosen AI red...
OpenAI back on top as GPT-5.2 calms competition concerns: Jefferies
07:56am, Friday, 12'th Dec 2025
OpenAI has quickly reasserted its lead in the AI race following concerns it was falling behind Google, analysts at Jefferies say, pointing to the release of...
Costco posts strong Q1 results as digital sales surge
03:54am, Friday, 12'th Dec 2025
Costco Wholesale Corporation (NASDAQ:COST, XETRA:CTO) reported an 8% rise in first-quarter revenue on Thursday aftermarket, lifted by robust digital...
Jiangxi Copper ups its approach for SolGold with 28p-a-share proposal
03:31am, Friday, 12'th Dec 2025
SolGold PLC (LSE:SOLG, TSX:SOLG, OTC:SLGGF) has confirmed it is warming to a sweetened takeover proposal from Jiangxi Copper, which has lifted its...
OKYO Pharma reports favorable outcomes from Phase 2 neuropathic corneal pain study
09:44am, Thursday, 11'th Dec 2025
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing treatments for neuropathic corneal pain (NCP), said patients treated with its investigational therapy urcosimod in
OKYO Pharma reports favorable outcomes from Phase 2 neuropathic corneal pain study
04:40am, Thursday, 11'th Dec 2025
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing treatments for neuropathic corneal pain (NCP), said patients treated...
OKYO Pharma Announces Chairman and Founder Acquires Shares
07:00am, Wednesday, 03'rd Dec 2025
LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic cornea
